ClinicalTrials.gg
CompletedNCT04102267Updated Sep 26, 2019

Extended Delivery of Bupivacaine Study in Herniorrhaphy

A Phase 4 interventional study of Bupivacaine liposome injectable suspension and Bupivacaine HCl without epinephrine via continuous infusion in Analgesia, sponsored by Heron Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by Heron Therapeutics · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2018, 8 years 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2018, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Hernia, Inguinal with a site in United States — 9 open to participants now, 20 under way, none of them phase 3. Hernia, Inguinal · United States.

Enrollment
50th of 60
32 · median 100
Started
2018
with 4 others
Phase 4
10 of 77
none open now
Registered
49th of 77
by date
Lead sponsor
4 of 77
Heron Therapeutics

Among the 77 studies in Hernia, Inguinal with a site in United States, this one is the 50th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2018, is one of 10 in phase 4, and was the 49th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

9 of the 77 studies in Hernia, Inguinal with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hernia, Inguinal with a site in United States, or all of them as a file.
02

Study summary

This is a phase 4, randomized, open-label study of the efficacy, safety, and pharmacokinetics of bupivacaine administered as liposomal bupivacaine or continuous infusion via elastomeric pump following unilateral open inguinal herniorrhaphy.

03

Conditions studied

  • Analgesia

Keywords

  • herniorrhaphy
  • inguinal hernia
  • hernia
  • hernia surgery
  • postoperative pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia
  • Has an Physical Status of I, II, or III
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile,or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Had any prior inguinal hernia repair
  • Has a planned concurrent surgical procedure
  • Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
  • Has taken any NSAIDs within least 10 days prior to the scheduled surgery
  • Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting)
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
  • Has been administered systemic within 5 half-lives or 10 days prior to administration of study drug
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments
  • Has a known history of , (HIV), or active
  • Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half-lives
  • Has undergone 3 or more surgeries within 12 months
  • Has a (BMI) >39 kg/m2.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Liposomal bupivacaine injection (Group 1)

    Liposomal bupivacaine 266 mg via injection

    Drug: Bupivacaine liposome injectable suspension

  • Experimental
    Bupivacaine HCl continuous infusion (Group 2)

    Bupivacaine HCl 300 mg via continuous infusion

    Drug: Bupivacaine HCl without epinephrine via continuous infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC0-72)

    Time frame: 72 hours

Secondary outcomes

  1. Total postoperative opioid consumption (in morphine equivalents)

    Time frame: 72 hours

  2. Proportion of subjects who are opioid-free

    Time frame: 72 hours

  3. Median time in hours to first opioid rescue medication

    Time frame: 72 hours

  4. Mean AUC0-72 of the NRS-R pain intensity scores.

    Time frame: 72 hours

07

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Jul 2, 2018
Primary completionActual
Sep 3, 2018
CompletionActual
Oct 26, 2018
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04102267
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Jul 2, 2018
Primary completion
Sep 3, 2018
Completion
Oct 26, 2018
Last update
Sep 26, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion